
Development of a gene therapy for the targeted treatment of right heart failure

Dr. med. Philipp Schlegel

Medical Faculty, Institute for Cardiomyopathies, Heidelberg University Hospital

Right heart failure is a serious complication of pulmonary arterial hypertension, associated with significant morbidity and mortality. Despite advances in the treatment of pulmonary arterial hypertension, there are no specific therapies for right heart failure.

Preliminary work has shown that targeted gene therapeutic expression of a human receptor in cardiomyocytes can have beneficial effects in various cardiac diseases, including chronic heart failure. In view of the high demand for specific therapies for right heart failure, the researchers aim to test the described gene therapeutic approach using a preclinical animal model of right heart failure. The project includes the definition of the optimal gene dose in the animal model, followed by an initial proof-of-concept study.
